ABT-239

ABT-239
Identifiers
	IUPAC name 4-(2-{2-[(2R)-2-Methylpyrrolidin-1-yl]ethyl}-; benzofuran-5-yl)benzonitrile;
CAS Number	460746-46-7 ; 460746-51-4 (racemic); 460749-29-5 (S-isomer);
PubChem CID	9818903;
IUPHAR/BPS	1218;
ChemSpider	7994652 ;
UNII	86H6B395PI;
ChEMBL	ChEMBL351231 ;
CompTox Dashboard (EPA)	DTXSID00196710 ;
Chemical and physical data
Formula	C22H22N2O
Molar mass	330.431 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES N#CC1=CC=C(C2=CC3=C(C=C2)OC(CCN4[C@@H](CCC4)C)=C3)C=C1;
	InChI InChI=1S/C22H22N2O/c1-16-3-2-11-24(16)12-10-21-14-20-13-19(8-9-22(20)25-21)18-6-4-17(15-23)5-7-18/h4-9,13-14,16H,2-3,10-12H2,1H3/t16-/m1/s1 ; Key:KFHYZKCRXNRKRC-MRXNPFEDSA-N ;
	(verify)

ABT-239 is an H₃-receptor inverse agonist developed by Abbott. It has stimulant and nootropic effects, and has been investigated as a treatment for ADHD, Alzheimer's disease, and schizophrenia. ABT-239 is more active at the human H₃ receptor than comparable agents such as thioperamide, ciproxifan, and cipralisant. It was ultimately dropped from human trials after showing the dangerous cardiac side effect of QT prolongation, but is still widely used in animal research into H₃ antagonists / inverse agonists.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.